Arcus Biosciences (NYSE:RCUS) Shares Down 4.9% – Should You Sell?

Arcus Biosciences, Inc. (NYSE:RCUS)’s share price was down 4.9% during trading on Wednesday. The company traded as low as $22.94 and last traded at $22.5750. 278,770 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 1,322,284 shares. The stock had previously closed at $23.75.

Key Stories Impacting Arcus Biosciences

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: New ARC-20 data for casdatifan showed promising progression-free survival and response rates across first-line, second-line and later-line clear-cell kidney cancer settings, with a manageable safety profile. The results strengthen the potential of Arcus’s lead program, although additional clinical and regulatory hurdles remain. Casdatifan kidney cancer data
• Positive Sentiment: Truist raised its price target for RCUS to $41 from $40 and maintained a Buy rating, while Wedbush increased its target to $49 from $43 and kept an Outperform rating. The targets imply substantial upside if casdatifan development and commercialization progress as expected. Truist price target Wedbush price target
• Neutral Sentiment: Arcus estimated that it held approximately $694 million in cash, cash equivalents and marketable securities at September 30, 2026. This provides funding for ongoing clinical programs, but the company remains loss-making and continues to require significant investment.
• Negative Sentiment: Arcus priced a public offering of 14.29 million shares at $17.50 per share, generating gross proceeds of $250 million. The financing improves liquidity but is dilutive to existing shareholders and was priced below the prior trading level, contributing to a sharp recent decline in the stock. Arcus stock offering pricing
• Negative Sentiment: A shareholder law firm announced an investigation into potential fiduciary-duty violations and alleged self-dealing by company officers and directors. The investigation is preliminary, but it adds reputational and legal uncertainty for investors. Shareholder investigation

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Wells Fargo & Company boosted their price objective on Arcus Biosciences from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 6th. Wall Street Zen raised Arcus Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. Truist Financial raised their target price on Arcus Biosciences from $40.00 to $41.00 and gave the company a “buy” rating in a report on Wednesday. TD Cowen initiated coverage on Arcus Biosciences in a research report on Wednesday, September 16th. They issued a “buy” rating on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a report on Friday, September 11th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $39.64.

Arcus Biosciences Trading Up 1.9%

The company has a current ratio of 3.82, a quick ratio of 3.82 and a debt-to-equity ratio of 0.22. The business’s fifty day simple moving average is $26.34 and its two-hundred day simple moving average is $26.20. The stock has a market capitalization of $2.48 billion, a P/E ratio of -4.99 and a beta of 0.94.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.17. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The company had revenue of $41.00 million for the quarter, compared to analyst estimates of $21.98 million. The firm’s quarterly revenue was down 74.4% compared to the same quarter last year. As a group, analysts forecast that Arcus Biosciences, Inc. will post -3.55 earnings per share for the current year.

Insider Buying and Selling at Arcus Biosciences

In related news, CAO Alexander Azoy sold 2,827 shares of Arcus Biosciences stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $30.00, for a total transaction of $84,810.00. Following the sale, the chief accounting officer directly owned 39,581 shares of the company’s stock, valued at $1,187,430. This trade represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Arcus Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in RCUS. Sterling Capital Management LLC lifted its position in Arcus Biosciences by 328.4% in the third quarter. Sterling Capital Management LLC now owns 2,716 shares of the company’s stock worth $70,000 after purchasing an additional 2,082 shares during the period. GAMMA Investing LLC boosted its stake in Arcus Biosciences by 22.4% during the third quarter. GAMMA Investing LLC now owns 4,855 shares of the company’s stock worth $125,000 after buying an additional 889 shares in the last quarter. WINTON GROUP Ltd boosted its stake in Arcus Biosciences by 59.7% during the second quarter. WINTON GROUP Ltd now owns 52,398 shares of the company’s stock worth $1,615,000 after buying an additional 19,578 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in Arcus Biosciences in the 2nd quarter valued at $30,000. Finally, Arizona State Retirement System increased its holdings in Arcus Biosciences by 1.7% in the 2nd quarter. Arizona State Retirement System now owns 24,211 shares of the company’s stock valued at $746,000 after buying an additional 409 shares during the period. 92.89% of the stock is currently owned by institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets.